- Home
- TLSI vs DMF Comparison
TLSI vs DMF Comparison
Compare TLSI & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- DMF
- Stock Information
- Founded
- TLSI 2010
- DMF 1988
- Country
- TLSI United States
- DMF United States
- Employees
- TLSI N/A
- DMF N/A
- Industry
- TLSI Medical Specialities
- DMF Finance/Investors Services
- Sector
- TLSI Health Care
- DMF Finance
- Exchange
- TLSI Nasdaq
- DMF Nasdaq
- Market Cap
- TLSI 150.3M
- DMF 149.8M
- IPO Year
- TLSI N/A
- DMF N/A
- Fundamental
- Price
- TLSI $4.93
- DMF $7.11
- Analyst Decision
- TLSI Strong Buy
- DMF
- Analyst Count
- TLSI 6
- DMF 0
- Target Price
- TLSI $11.75
- DMF N/A
- AVG Volume (30 Days)
- TLSI 33.1K
- DMF 60.7K
- Earning Date
- TLSI 11-14-2024
- DMF 01-01-0001
- Dividend Yield
- TLSI N/A
- DMF 2.66%
- EPS Growth
- TLSI N/A
- DMF N/A
- EPS
- TLSI N/A
- DMF 0.15
- Revenue
- TLSI $26,891,000.00
- DMF N/A
- Revenue This Year
- TLSI $60.96
- DMF N/A
- Revenue Next Year
- TLSI $53.65
- DMF N/A
- P/E Ratio
- TLSI N/A
- DMF $45.13
- Revenue Growth
- TLSI 67.90
- DMF N/A
- 52 Week Low
- TLSI $3.50
- DMF $5.37
- 52 Week High
- TLSI $10.42
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- TLSI 56.22
- DMF 47.43
- Support Level
- TLSI $4.53
- DMF $6.96
- Resistance Level
- TLSI $4.92
- DMF $7.18
- Average True Range (ATR)
- TLSI 0.29
- DMF 0.08
- MACD
- TLSI -0.02
- DMF 0.01
- Stochastic Oscillator
- TLSI 50.63
- DMF 60.71
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.